Impact of amyloid imaging on drug development in Alzheimer's disease☆
To access this article, please choose from the options below
☆ GE Healthcare holds a license agreement with the University of Pittsburgh based on the [11C]PiB imaging technology described in this article but provided no financial support for the preparation of this article and had no role in the writing or interpretation of the information contained in this article. Drs. Mathis and Klunk are co-inventors of [11C]PiB and, as such, have a financial interest in this license agreement.
PII: S0969-8051(07)00177-1
doi:10.1016/j.nucmedbio.2007.06.015
© 2007 Elsevier Inc. All rights reserved.
